Isodiol International Inc. (CSE:ISOL) (OTC:ISOLF) (FSE:LB6A.F) (the “Company” or “Isodiol”), specializes in the development of pharmaceutical and health and wellness products and is now supporting the pharmaceutical industry at large with its recently approved CBD as an Active Pharmaceutical Ingredient.
Isodiol International Inc. is focused on the nutritional health benefits that are derived from hemp and is a product development, sales, marketing and distribution company of hemp-based consumer products and solutions. The company specializes in identifying emerging trends and opportunities from all Cannabinoids available in hemp. Through the development of its own IP, Isodiol has been able to create a portfolio of products which are sold through various channels domestically in the US, and internationally.
Isodiol has the commercialized a 99%+ pure, naturally isolated CBD, including micro-encapsulations, and nano-technology for quality consumable and topical skin care products. Most recently, the company received approval for its CBD designated as an Active Pharmaceutical Ingredient for use in Finished Pharmaceutical Products as was announced April 26, 2018. This approval was obtained by the Medicines and Healthcare products Regulatory Agency of the UK.
The Company’s growth strategy includes the development of over-the-counter and pharmaceutical drugs, expanding its phytoceutical portfolio and will aggressively continue International expansion into Latin America, Asia and Europe.
Get access to more exclusive Pharmaceutical Stock profiles here.